ArticleDiscover oncology2025
Machine learning-Based integration develops a metastasis-Related rhythmic gene signature for improving outcomes in pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundCircadian dysregulation has been shown to be associated with the progression of pancreatic cancer (PC). However, the circadian machinery comprises numerous circadian rhythm-related genes (CRRGs), whose roles in tumor biology remain unclear.
methodsA metastasis-related rhythmic gene signature (MRRGS) was established based on differentially expressed genes (DEGs) identified from public PC datasets. A risk model was developed, and Gene Set Enrichment Analysis (GSEA) was employed to explore functional differences between low-risk and high-risk groups. The impact of MRRGS was further assessed through mutation and copy number variation (CNV) analysis. The correlation between modeling genes and immune infiltration scores was examined using the ESTIMATE, xCell, and ssGSEA algorithms. Finally, potential therapeutic drugs were tested in various PC patient populations.
resultsFive CRRGs, including S100A10, CD47, UBXN1, ERBB3, and ST3GAL1, were identified and validated for the development of the risk model. GSEA analysis revealed that high-risk PC patients were associated with ribosome-related pathways and MHC class II pathways. Mutation and CNV analyses indicated that high-risk patients exhibited SMAD4 mutations and a higher frequency of CNVs, while low-risk patients displayed significant alterations in genes such as GSTM1, CFHR3, and RNF43. Furthermore, results from the ESTIMATE, xCell, and ssGSEA analyses demonstrated a notable negative correlation between the ERBB3 and S100A10 genes and immune infiltration-related genes. Based on drug screening outcomes, Sepatronium bromide is recommended for drug trials in high-risk populations, while SB505124 is suggested for low-risk populations.
conclusionsThe MRRGS constructed from S100A10, CD47, UBXN1, ERBB3, and ST3GAL1 may serve as predictors of prognosis and drug sensitivity for PC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.